Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
    • 50th Volume Reprints
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
LetterLetter

Paradoxical Nodular Scleritis during Tocilizumab Therapy: A Case Report

EUGENE MICHAEL, EVA L. LANGE and STEPHEN GUEST
The Journal of Rheumatology November 2017, 44 (11) 1760-1761; DOI: https://doi.org/10.3899/jrheum.170234
EUGENE MICHAEL
Meade Clinical Centre, Department of Ophthalmology, Waikato District Health Board;
Roles: Ophthalmology Registrar
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: EugeneM@adhb.govt.nz
EVA L. LANGE
Meade Clinical Centre, Department of Rheumatology, Waikato District Health Board;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
STEPHEN GUEST
Meade Clinical Centre, Department of Ophthalmology, Waikato District Health Board, Hamilton, New Zealand.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

To the Editor:

Ocular manifestations can result from interleukin 6 (IL-6) inhibition, and they should be considered as a possible paradoxical complication when treating inflammatory arthritis.

We report the case of a 48-year-old woman with a background history of rheumatoid arthritis (RA), pyoderma gangrenosum, and systemic lupus erythematosus who was diagnosed with anterior nodular scleritis following initiation of tocilizumab (TCZ) therapy. Her RA remained active despite being treated with rituximab (RTX) 2 g intravenously every 6 months, methotrexate (MTX) 20 mg orally every week, sulfasalazine 1 g orally twice daily, hydroxychloroquine 200 mg orally once daily, and folic acid 5 mg orally every week. She was switched to TCZ 8 mg/kg intravenously every 4 weeks. RTX was stopped 5 months prior to TCZ because of primary failure. MTX was discontinued immediately prior to TCZ owing to government funding requirements whereby TCZ can only be given as monotherapy. Following the first dose of TCZ, her RA went into clinical remission, with a 28-joint Disease Activity Score of 2.41 from 6.28 prior. In addition, the inflammatory markers were at a nadir (C-reactive protein went from 28 to < 1) not seen in 2 years. Emergence of the lesion shown in Figure 1 occurred following the second dose of TCZ. A clinical diagnosis of nodular scleritis was formulated and this responded to oral prednisone: a dose of 20 mg daily tapered over 3 months. Moreover, concomitant withdrawal of TCZ therapy saw complete resolution of the nodular lesion at 9 months (Figure 2), while she took no steroids. Ophthalmological examination using the slit-lamp showed no other signs of intraocular inflammation. A full blood count, tuberculosis blood test, and Treponema screen were performed, and infectious etiology excluded. It was posited that this was a paradoxical effect of the TCZ treatment, given that the patient’s inflammatory profile was suppressed, she had never experienced extra-articular manifestations before, and considering the temporal relationship with commencement of TCZ.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

A 4-mm raised scleral nodule in the super-limbal region was noted following tocilizumab therapy.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Complete resolution of scleral nodule at 9 months following the cessation of tocilizumab therapy.

Paradoxical reactions may be defined as “the occurrence with therapy with a biological agent, of a pathological condition that usually responds to this class of drug1.” This may be further subclassified into true reactions: for example, the onset of de novo psoriasis during RTX therapy (or in parallel — the exacerbation of a preexisting condition upon starting a biological agent), or borderline reactions. The latter exist when a biological agent has a theoretical rationale for its efficacy in treating a certain condition (but is not registered for it), yet gives rise to the development of that condition1.

TCZ is an anti–IL-6 receptor monoclonal antibody, thereby conferring its antiinflammatory properties through this mechanism. Elevated levels of IL-6 have been detected in the eyes of patients with refractory uveitis and thus TCZ may have an important role in the treatment of ocular inflammation2. TCZ has demonstrated efficacy in the treatment of RA3, recalcitrant uveitis and its associated macular edema2, and treatment-refractory scleritis4,5,6. It is approved for usage by the US Food and Drug Administration in RA and in polyarticular or systemic juvenile idiopathic arthritis2.

Case reports of paradoxical reactions with TCZ therapy have been documented. Laurent, et al mentions 2 instances of psoriatic reactivation following TCZ initiation7. Similarly, a single account was noted of a patient developing psoriasiform palmoplantar pustulosis when having TCZ for treatment of RA. The rash abated upon discontinuation of therapy8. A possible case report of TCZ-induced sarcoidosis has also been described in a 40-year-old woman with RA, in whom other biological agents (etanercept and certolizumab) had been used without such incidence9.

Despite these reports, the onset of ocular inflammation with TCZ is rarely reported in literature. In 1 anecdote, a 41-year-old man with HLA-B27–positive ankylosing spondylitis experienced his first-ever episode of acute anterior uveitis between the second and third doses of TCZ. In another report, a 65-year-old man developed peripheral ulcerative keratitis following 11 months of TCZ. Systems review and infection screening were unyielding. Relapse of keratitis occurred 20 days after the third infusion, therefore TCZ was withheld for 2 months. After reintroduction of therapy 19 days later, a third episode of keratitis occurred. In these 2 cases, it is worth considering that inflammatory eye disease is not paradoxical but an extraarticular feature of their rheumatological conditions. However, these manifestations had not occurred prior to TCZ, but during a period in which systemic inflammation was well controlled. In addition, a favorable systemic clinical response to TCZ was observed. Other causes of inflammation (such as infection) were excluded and in the case of keratitis, the rechallenge test was positive10.

Biological agents such as TNF antagonists may precipitate de novo uveitis or scleritis in situations where the patient’s rheumatological condition is controlled by such treatment. To our knowledge, this is the first example of nodular scleritis following TCZ therapy. A rechallenge of TCZ was offered to our patient, but she declined. We conclude that ocular manifestations as a result of IL-6 inhibition should be considered as a possible paradoxical phenomenon when treating inflammatory arthritis.

REFERENCES

  1. 1.↵
    1. Toussirot E,
    2. Aubin F
    . Paradoxical reactions under TNF-α blocking agents and other biological agents given for chronic immune-mediated diseases: an analytical and comprehensive overview. RMD Open 2016;2:e000239.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Mesquida M,
    2. Leszczynyska A,
    3. Llorenc V,
    4. Adan A
    . Interleukin-6 blockade in ocular inflammatory disease. Clin Exp Immunol 2014;176:301–9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Yamanaka H,
    2. Tanaka Y,
    3. Inoue E,
    4. Hoshi D,
    5. Momohara S,
    6. Hanami K,
    7. et al.
    Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study (REACTION study). Mod Rheumatol 2011;21:122–33.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Silpa-Archa S,
    2. Oray M,
    3. Preble JM,
    4. Foster CS
    . Outcome of tocilizumab treatment in refractory ocular inflammatory diseases. Acta Ophthalmol 2016;94:e400–6.
    OpenUrl
  5. 5.↵
    1. Tode J,
    2. Zeuner R,
    3. Saeger M,
    4. Roider J,
    5. Nolle B
    . Tocilizumab and steroid boli for treatment-resistant anterior necrotizing scleritis. Acta Ophthalmol 2015;93:e683–4.
    OpenUrl
  6. 6.↵
    1. Shimizu H,
    2. Nishioka H
    . Successful treatment with tocilizumab for refractory scleritis associated with relapsing polychondritis. Scand J Rheumatol 2017;25:1–2.
    OpenUrl
  7. 7.↵
    1. Laurent S,
    2. Le Parc JM,
    3. Clerici T,
    4. Breban M,
    5. Mahe E
    . Onset of psoriasis following treatment with tocilizumab. Br J Dermatol 2010;163:1364–5.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Palmou-Fontana N,
    2. Sánchez Gaviño JA,
    3. McGonagle D,
    4. García-Martinez E,
    5. Iñiguez de Onzoño Martin L
    . Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology 2014;228:311–13.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Nutz A,
    2. Pernet C,
    3. Combe B,
    4. Cohen J
    . Sarcoidosis induced by tocilizumab: a paradoxical event? J Rheumatol 2013;40:1773–4.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Wendling D,
    2. Dernis E,
    3. Prati C,
    4. Frisch E,
    5. Delbosc B
    . Onset of inflammatory eye disease under tocilizumab treatment for rheumatologic conditions: a paradoxical effect? J Rheumatol 2011;38:2284.
    OpenUrlFREE Full Text
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 44, Issue 11
1 Nov 2017
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Paradoxical Nodular Scleritis during Tocilizumab Therapy: A Case Report
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Paradoxical Nodular Scleritis during Tocilizumab Therapy: A Case Report
EUGENE MICHAEL, EVA L. LANGE, STEPHEN GUEST
The Journal of Rheumatology Nov 2017, 44 (11) 1760-1761; DOI: 10.3899/jrheum.170234

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Paradoxical Nodular Scleritis during Tocilizumab Therapy: A Case Report
EUGENE MICHAEL, EVA L. LANGE, STEPHEN GUEST
The Journal of Rheumatology Nov 2017, 44 (11) 1760-1761; DOI: 10.3899/jrheum.170234
Reddit logo Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • IgG4-Related Disease With Testicular Involvement: Association or Coincidence?
  • The Use of Tofacitinib Has a Potential Effect on Improving the Outcomes of Melanoma Differentiation–Associated Gene 5–Related Interstitial Lung Disease
  • Considerable Uncertainty About the Burden of Gout in the Middle East and North Africa Region
Show more Letter

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire